" class="no-js "lang="en-US"> Roy Shteren - Medtech Alert
Wednesday, October 01, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Roy Shteren

Roy Shteren

About Roy Shteren

Experienced Chief Executive Officer with a demonstrated history of working in the health wellness and fitness industry. Skilled in Entrepreneurship, Agile Methodologies, Strategic Partnerships, Physical Therapy, and Management. Strong business development professional with an MPHA focused in master in public health from Bar-Ilan University.
Co-Founder and CEO of WizeCare Ltd. established to change the way Physical Therapy is delivered and consumed.

Related Story

Artificial Intelligence

 MoveAI™ Technology by WizeCare Shapes the Future of Physical Rehabilitation | Pharmtech Focus

MoveAI™ Technology by WizeCare Shapes the Future of Physical Rehabilitation

November 11 2021

WizeCare, a health technology company leading the way in the delivery of intelligent, accessible, and exciting […]